MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the…
MaaT PharmaDecember 11, 2022
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference MaaT Pharma will…
MaaT PharmaNovember 29, 2022
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022 As of September 30, 2022,…
MaaT PharmaNovember 8, 2022
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November Lyon, France, November 7th, 2022,…
MaaT PharmaNovember 7, 2022
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH)…
MaaT PharmaNovember 3, 2022
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaOctober 7, 2022
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D activities in…
MaaT PharmaOctober 4, 2022
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview For the first…
MaaT PharmaSeptember 29, 2022
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September Lyon, France, September 8th,…
MaaT PharmaSeptember 8, 2022
